Renal DialysisHemodialysis Units, HospitalCapital ExpendituresDithioerythritolStrokeKidney Failure, ChronicEstrogen Replacement TherapyRenal Replacement TherapyHormone Replacement TherapyPeritoneal DialysisEnzyme Replacement TherapyDialysisDialysis SolutionsPeritoneal Dialysis, Continuous AmbulatoryTreatment OutcomeTime FactorsRisk FactorsBrain IschemiaProspective StudiesAcute Kidney Injuryalpha-GalactosidasePostmenopauseCerebrovascular DisordersIntensive Care UnitsFollow-Up StudiesFabry DiseaseRetrospective StudiesPeritonitisEstrogensProgestinsCohort StudiesHemodiafiltrationHemofiltrationMenopauseGaucher DiseasePeritoneumTobacco Use Cessation ProductsAdministration, CutaneousEstrogens, Conjugated (USP)IncidenceArthroplasty, Replacement, HipGlycogen Storage Disease Type IINephrologyNorethindroneClimactericArthroplasty, Replacement, KneeHypopituitarismCatheters, IndwellingGlucosylceramidaseNicotineHemodialysis SolutionsSmoking CessationAge FactorsRisk AssessmentHospital UnitsKidneys, ArtificialCerebral HemorrhageKidney DiseasesKidney TransplantationSeverity of Illness IndexRegistriesMedroxyprogesterone AcetateCerebral InfarctionIschemic Attack, TransientEstradiolHuman Growth HormoneCritical IllnessRecovery of FunctionN-Acetylgalactosamine-4-SulfataseHypothyroidismHypogonadismSurvival RateAcute DiseaseOvariectomyCase-Control StudiesUreaCreatinineUltrafiltrationalpha-GlucosidasesPrognosisPredictive Value of TestsComorbidityProportional Hazards ModelsHeart Valve Prosthesis ImplantationCardiovascular DiseasesArthroplasty, ReplacementMucopolysaccharidosis VIBiological MarkersHeart Valve ProsthesisIduronidaseStroke VolumeUnited StatesThyroxineSurvival AnalysisFibrinolytic AgentsAnticoagulantsNorpregnenesRiskPostoperative ComplicationsRenal Insufficiency